Attached files
file | filename |
---|---|
8-K - PRIMARY DOCUMENT - Bionik Laboratories Corp. | form8-kbionik6617.htm |
Bionik Laboratories, Inc. to Present at the 2017 Marcum MicroCap
Conference
TORONTO and BOSTON, June 7, 2017 -- Bionik Laboratories
Corp. (OTCQX:BNKL)
(“Bionik” or the "Company"), a robotics company focused
on providing rehabilitation and assistive technology solutions to
individuals with neurological and mobility challenges from hospital
to home, today announced that Peter Bloch, Chief Executive Officer,
will present at the 6th
Annual 2017 Marcum MicroCap Conference
on Friday, June 16, 2017 at 11:00am ET. The conference will be held
at The Grand Hyatt Hotel in New York City.
During his presentation, Mr. Bloch will provide a corporate update
and discuss Bionik’s propriety assistive robotic therapy
systems that are commercially available for treatment of stroke and
other neurological disorders, as well as new products currently
under development.
Management of Bionik Laboratories will be available for one-on-one
meetings at the conference on Thursday June 15 and Friday, June 16,
2017. Investors interested in arranging a meeting should contact
Amato and Partners, LLC by email: admin@amatoandpartners.com.
About the Marcum MicroCap Conference
The Marcum MicroCap Conference (www.marcummicrocap.com)
is a nationally recognized forum for publicly traded companies with
less than $500 million in market capitalization to
network with fund managers and high net worth investors who focus
on small cap equities. The conference is attended each year by more
than 2,000 investors and other participants from every segment of
the microcap marketplace, including venture and lower middle-market
private equity investors, institutional investors, directors,
investment bankers, and buy- and sell-side analysts, as well as
senior executive teams from presenting companies and service
providers to the microcap marketplace.
The conference is presented by Marcum LLP, a top national
accounting and advisory firm registered with the Public Company
Accounting Oversight Board (PCAOB). Marcum's Assurance Division
provides the most up-to-date service and guidance on SEC accounting
and reporting issues. Services include Financial Statement Audits
in accordance with PCAOB standards; Tax Compliance and Advisory
Services; Due Diligence; Agreed-Upon Procedures and Other Attest
Work; Internal Audit Services; Sarbanes-Oxley Section 404
Compliance Services and Software; Technical Accounting Assistance;
and IPO Assistance. For more information,
visit www.marcumllp.com.
About Bionik Laboratories
Bionik Laboratories (OTCQX:BNKL) is a robotics company focused on
providing rehabilitation and mobility solutions to individuals with
neurological and mobility challenges from hospital to home. The
Company has a portfolio of products focused on upper and lower
extremity rehabilitation for stroke and other mobility-impaired
patients, including three products on the market and four products
in varying stages of development. The InMotion Systems — the
InMotion ARM™, InMotion Wrist™, InMotion Hand™
and InMotion AnkleBot™ — are designed to provide
intelligent, patient-adaptive therapy in a manner that has been
clinically verified to maximize neuro-recovery. Bionik is also
developing a lower-body exoskeleton, ARKE™, designed to allow
paraplegics as well as other wheelchair users the ability to
rehabilitate through walking. ARKE is designed to continually adapt
to a patient’s ability and provide real-time feedback to the
physiotherapist.
For more information, please visit www.bioniklabs.com and
connect with us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons and
other robotic rehabilitation products, (ii) a projection of income
(including income/loss), earnings (including earnings/loss) per
share, capital expenditures, dividends, capital structure or other
financial items, (iii) the Company's future financial performance,
and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances, and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and
assumptions, and are subject to a number of risks and uncertainties
and other influences, many of which the Company has no control.
Actual results and the timing of certain events and circumstances
may differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain additional financing,
the significant length of time and resources associated with the
development of our products and related insufficient cash flows and
resulting illiquidity, the Company's inability to expand the
Company's business, significant government regulation of medical
devices and the healthcare industry, lack of product
diversification, volatility in the price of the Company's raw
materials, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. The Company does not undertake to update these
forward-looking statements.
Media contact:
Matt
Bretzius
FischTank
Marketing and PR
matt@fischtankpr.com
Investor Relations contact:
Amato
and Partners, LLC
Investor
Relations Counsel
admin@amatoandpartners.com